Demographic, Metabolic, and Genomic Description of Neonates With Severe Hyperbilirubinemia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

450 participants

Study Classification

OBSERVATIONAL

Study Start Date

2006-09-30

Study Completion Date

2007-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to compare the demographic, metabolic, and genomic characteristics of patients who develop severe hyperbilirubinemia to patients who never developed a significant bilirubin level.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Selective Use of Antibiotics in Neonates Born to Mothers With Suspected Chorioamnionitis

NCT03576560

Chorioamnionitis

COMPLETED

Comparison of the Effectiveness of Two Different Antibiotic Regimens of the Treatment of Pregnant Women With Preterm Rupture of Membranes

NCT04528251

Preterm Membrane Rupture Neonatal Sepsis

UNKNOWN

Determination of Gentamicin Dosing in Neonatal Patients

NCT00198601

Infection

COMPLETED PHASE4

Infant Immune Response to Bacterial Infection

NCT00546195

Prematurity Histologic Chorioamnionitis

COMPLETED

Clinical Outcome of Neonates With GBS Positive Culture-12 Year Retrospective Study

NCT00326313

Infants With Positive GBS Bacteremia

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this study is to compare the demographic, metabolic, and genomic characteristics of patients who develop severe hyperbilirubinemia (serum bilirubin level in the "high risk zone of greater than the 95th percentile based on the Bhutani nomogram) to patients who never developed significant hyperbilirubinemia (bilirubin level in "low risk zone of less than the 40th percentile" on Bhutani nomogram and who did not require any treatment for hyperbilirubinemia). Our primary goal is to determine if common gene mutations occur at a greater frequency in patients with severe hyperbilirubinemia than in neonates without significant hyperbilirubinemia.

The gene mutations we will test for are:

* Glucose-6-phosphate Dehydrogenase Deficiency \[G6PD\] gene mutations
* African A- mutation (G202A;A376G)
* The common Mediterranean mutation (C563T)
* Two common Chinese mutations (G1376T and G1388A)
* UGT1A1 polymorphism. The UGT1A1 gene polymorphisms refer to those genetic defects found to be associated with Gilbert's Syndrome, including a promoter defect (T-3263G) that disrupts a transcription regulatory site, the TA repeats promoter polymorphism, and four mutations within the coding region (G211A, C686A, C1091T, and T1456G).
* Gene polymorphism for the organic anion transporting protein (OATP-2)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hyperbilirubinemia Jaundice

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Gene mutation sample

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Case

* Documentation of informed consent.
* Gestational age greater than or equal to 37 weeks.
* Birth weight greater than or equal to 2000 grams.
* At least one serum bilirubin level that is greater than the 95th percentile ("high risk zone") based on the Bhutani nomogram(1), for the case population.
* Age at enrollment less than 7 days or less than or equal to 168 hours.
* No major anomalies (chromosomal abnormalities, cyanotic congenital heart disease, gastroschisis, omphalocele, diaphragmatic hernia, or other major gastrointestinal anomalies, major neurological injury or anomaly, and multiple congenital anomalies).
* Ability to follow subjects transferred to another facility for outcome data.

Control

* Documentation of informed consent.
* Gestational age greater than or equal to 37 weeks.
* Birth weight greater than or equal to 2000 grams.
* At least one estimate of serum bilirubin. Bilirubin level estimated to be less than the 40th percentile ("low risk zone") based on the Bhutani nomogram. While a serum bilirubin in the low risk zone is the preferred method for assessing the bilirubin level, many pediatricians use transcutaneous measure of bilirubin as a screening tool for identifying "low risk" patients. For this reason, we will allow controls to be identified using transcutaneous measurements and collect serum bilirubin levels only as clinically indicated.
* Age at enrollment less than 7 days or less than or equal to 168 hours.
* No major anomalies (chromosomal abnormalities, cyanotic congenital heart disease, gastroschisis, omphalocele, diaphragmatic hernia or other major gastrointestinal anomalies, major neurological injury or anomaly, and multiple congenital anomalies).
* Ability to follow subjects transferred to another facility for outcome data.

Exclusion Criteria

Case and Control

* Gestational age less than 37 weeks.
* Birth weight less than 2000 grams.
* Older than 7 days of age or 168 hours.
* Any major congenital anomalies.

Maximum Eligible Age

6 Days

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes